Linked Life Data

14970301

Source:http://linkedlifedata.com/resource/pubmed/id/14970301

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
940
pubmed:dateCreated
2004-2-18
pubmed:abstractText
Drug metabolism may be perturbed by genetically determined differences in the metabolic activity of cytochrome P450 enzymes. The authors encountered extensive bleeding in a patient receiving warfarin for anticoagulation after the introduction of celecoxib, an anti-inflammatory drug. As the CYP2C9 enzyme metabolises these drugs, it was determined whether variant alleles were responsible for altering warfarin handling. Genetic analysis established that the patient was a compound heterozygote with CYP2C9*2 and *3 variant alleles, which exhibit lower drug metabolising capacity and enhance susceptibility to drug toxicity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0032-5473
pubmed:author
pubmed:issnType
Print
pubmed:volume
80
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
107-9
pubmed:dateRevised
2009-10-22
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication.
pubmed:affiliation
Marion Bessin Liver Research Center and Department of Medicine, Albert Einstein College of Medicine, New York, USA.
pubmed:publicationType
Journal Article, Case Reports